Rituximab and Anti-Rituximab Antibody, DoseASSURE™ RTX
Also known as: Anti-CD20, Biologics, Biopharmaceutical, DoseASSURE, Rituxan®
Use
Therapeutic monitoring of rituximab and antidrug antibody development for individuals with non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and rheumatoid arthritis. This test provides rituximab drug concentration as well as the level of anti-rituximab antibodies.
Special Instructions
This test includes Serial Monitoring.
Limitations
Failure of rituximab therapy may not always be due to the presence of anti-rituximab antibodies. Conversely, the absence of anti-rituximab antibodies does not guarantee positive response to treatment. High serum biotin concentrations in patients taking biotin supplements may cause an interference in this assay. Patients may be advised to stop biotin consumption at least 72 hours prior to sample collection.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 82467-2
- 82466-4
Result Turnaround Time
12-16 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
3 mL
Minimum Volume
1 mL
Container
Gel-barrier tube, red-top tube, or serum transfer tube
Collection Instructions
Serum must be separated from cells within 45 minutes of venipuncture. Submit serum in a plastic transport tube. To avoid delays in turnaround time when requesting multiple test on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Refrigerate or freeze
Causes for Rejection
Gross hemolysis; gross lipemia; icteric specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 14 days |
| Frozen | 14 days |